Apitope aims to tap the Brussels Euronext stock market for funds to progress a promising pipeline of antigen-specific immunotherapies for treating autoimmune diseases, firstly its multiple sclerosis treatment candidate ATX-MS-1467 in relapsing MS.
Founded in 2002 as a spin-out from the University of Bristol, Apitope is now based in Diepenbeek, Belgium where its research and finance activities are based while its development and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?